Thymosin Alpha-1 (TA-1) is the cleanest peptide-to-mainstream-medicine bridge you'll find in this space. It's a 28-amino-acid peptide originally pulled from calf thymus extract and fully sequenced by Allan Goldstein's lab in the 1970s (Goldstein et al., PNAS, 1977). Your thymus makes it. It runs T-cell maturation, innate immune activation, and the cytokine signalling that adaptive immunity relies on. The Khavinson bioregulator tradition takes this seriously, but TA-1 is further along the regulatory path than the rest of that class: it's approved as Zadaxin in 40+ countries, with thousands of trial patients behind it (King & Tuthill, Ann NY Acad Sci, 2007).
Key Takeaways
- —Thymosin Alpha-1 (TA-1) is a 28-aa endogenous thymic peptide sold as Zadaxin, approved in 40+ countries and holding FDA Orphan Drug status for multiple conditions.
- —A meta-analysis of 12 RCTs in chronic hepatitis B showed TA-1 combination therapy hit 2.4× higher seroconversion rates vs interferon alone (Zhang et al., World Journal of Gastroenterology, 2005).
- —Three RCTs in severe COVID-19 patients (2020–2021) showed TA-1 cut 28-day mortality and ICU admission rates compared to standard care.
- —Standard clinical dose is 1.6 mg subq twice weekly, the same protocol used in the hepatitis B and malignant melanoma trials.
TA-1 is the N-terminal 28-amino-acid fragment of prothymosin alpha, a nuclear protein expressed in basically every mammalian cell. The thymus produces TA-1 as part of the system that educates naive T-cells: differentiating CD4+ helper and CD8+ cytotoxic T-cells, and teaching them what counts as self.
Four mechanisms do the heavy lifting:
Toll-Like Receptor (TLR) signalling: TA-1 acts as a TLR2 and TLR9 agonist, switching on dendritic cells and triggering the innate cascade (Romani et al., Blood, 2004). TLR9 activation drives type I interferon, which is the front-line antiviral response. That's why TA-1 keeps showing up in viral indications.
T-cell differentiation and maturation: TA-1 pushes immature thymocytes into functional CD3+ T-cells, upregulates surface markers (CD2, CD3, CD4, CD8), and bumps MHC class I expression on tumour cells, which is how malignant cells become visible to cytotoxic T-lymphocytes again.
NK cell activation: Natural killer cell cytotoxicity goes up with TA-1 treatment. That contributes to both anti-viral and anti-tumour effects.
Cytokine balance modulation: TA-1 polarises toward Th1 (IL-2, IFN-γ, TNF-α) while modulating Th2 and Th17, including direct upregulation of IL-2 receptor expression and Treg compartment expansion (Sztein et al., J Immunol, 1986). In immunocompromised users, that shift is what enables actual viral clearance.
Thymosin Alpha-1 activates Toll-Like Receptors 2 and 9 on dendritic cells and macrophages, triggering type I interferon production and pushing Th1 polarisation. This mechanism explains clinical efficacy across viral infections (hepatitis B, COVID-19) and malignant conditions where T-cell-mediated cytotoxicity isn't getting the job done. Standard clinical dose is 1.6 mg subq twice weekly (Zadaxin protocol).
The hepatitis B data is where TA-1 separates itself from the rest of the bioregulator class. A 2005 meta-analysis (Zhang et al., World J Gastroenterol, 2005) pooled 12 randomised controlled trials:
A Cochrane-style systematic review (Yang et al., World J Gastroenterol, 2016) covering 12 trials and over 900 patients confirmed it, reporting significantly higher combined response rates for TA-1 plus interferon vs interferon alone at end-of-treatment and 6-month follow-up.
Twelve RCTs covering thousands of patients is a clinical evidence base most peptides in this space will never see. That's what makes TA-1 different from aspirational longevity peptides. It has demonstrated clinical utility on a hard endpoint, viral clearance, in prospective, randomised, controlled conditions. You're not extrapolating from a rat model.
Three RCTs in 2020–2021 looked at TA-1 in severe COVID-19:
Liu et al. (2020) — 76 severe COVID-19 patients with lymphocytopenia. TA-1 group had significantly lower 28-day mortality (11.1% vs 30.0%), faster lymphocyte recovery, and restored lymphocyte numbers vs standard care (Liu et al., Clinical Infectious Diseases, 2020).
Shi et al. (2021) — TA-1 reduced ICU admission and mechanical ventilation in hospitalised patients. Lymphocyte count recovery was markedly faster.
Wu et al. (2021) — Multicentre retrospective; TA-1 adjunct cut 28-day mortality and progression to severe disease vs standard care alone (Wu et al., Int Immunopharmacol, 2021).
The mechanistic story tracks. Severe COVID-19 involves lymphopenia, impaired innate immunity, and cytokine dysregulation, all areas where TA-1 has established activity. This isn't a stretch.
The Zadaxin protocol carries across the hepatitis B programme, the malignant melanoma combination trials with DTIC plus interferon (Maio et al., J Clin Oncol, 2010), Italian ICU severe sepsis studies (Wu et al., Critical Care, 2013), and the COVID-19 trials:
| Parameter | Value |
|---|---|
| Dose | 1.6 mg per injection |
| Route | Subcutaneous |
| Frequency | Twice weekly |
| Duration | 6 months (hepatitis B); variable for other indications |
| Reconstitution | Supplied pre-mixed as Zadaxin; research grade lyo requires BAC water |
For immune protocols outside the trial setting, most people run 1.6 mg subq twice weekly for 4–12 weeks, with cycles repeated 1–2× per year. Some run lower doses (0.8–1.6 mg) 1–3× per week for shorter acute cycles, especially if they're chasing a specific event like a post-COVID recovery or a flare.
TA-1 has one of the cleanest safety profiles in this space, and it's not close. That's downstream of two facts: it's an endogenous thymic peptide your body already makes, and it's been used clinically across 40+ countries under Zadaxin. Adverse event data from trials covering thousands of patients reports:
TA-1's 40-country clinical approval and Orphan Drug status make it one of the most evidence-backed peptides in this space, but that doesn't mean every source selling it is G2G. The Next Pep peptide library covers the full 28-aa thymic peptide profile: Th1/Th2 immune modulation mechanism, Zadaxin regulatory status, the hepatitis B meta-analysis numbers, and the COVID-19 RCT mortality findings, all in one verified reference.
Use the comparison tool to put Thymosin Alpha-1 alongside BPC-157 or other immune-modulating peptides you're researching, side-by-side across mechanism, evidence quality, and regulatory status. The dosing calculator handles reco for the standard 1.6 mg subq protocol or any custom dose: enter your vial concentration and it returns exact draw volume and syringe units.
Zadaxin is the brand name for synthetic Thymosin Alpha-1 made by SciClone Pharmaceuticals. It's the same 28-amino-acid peptide as research-grade TA-1. Zadaxin is approved in 40+ countries for chronic hepatitis B and used off-label for hepatitis C, malignant melanoma adjuvant therapy, and more recently as an immunomodulator in severe infections. It holds FDA Orphan Drug status.
TA-1's primary effect is immune normalisation and Th1 polarisation, not non-specific immune "boosting." In immunocompromised users (viral infection, cancer chemo, severe illness) it restores depleted T-cell function. In immunocompetent subjects, the effect is more modulatory, improving immune response quality without overactivation. It doesn't work like a stimulant.
The clinical case is strongest for viral and intracellular bacterial infections where T-cell-mediated immunity is doing the work. Published data covers hepatitis B, hepatitis C (adjunct to interferon), respiratory viral infections, and sepsis. The mechanistic case for recurring herpes, EBV reactivation, and Lyme co-infections is plausible but doesn't have the same RCT-level evidence. Anecdotally, this is where a lot of chronic-illness users run it.
Different systems, different jobs. TA-1 is an immune modulator: T-cell differentiation, dendritic cell activation, viral clearance. BPC-157 is a mucosal healing peptide working through VEGFR2–eNOS angiogenesis and FAK-paxillin cell migration, so its effects are tissue repair, gut healing, tendon work. They stack without mechanistic interference.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
CJC-1295 with DAC has a 6-8 DAY half-life; Modified GRF (1-29) clears in ~30 minutes. Same modified GHRH(1-29) backbone, one bolt-on linker, ~1,000x PK difference.
TB-500 is a 7-aa fragment of thymosin beta-4 (43 aa, ~4,963 Da), not the full protein. Cross-COA review: ~67% of "TB-500" vials are actually full Tβ4.